Morgan Stanley analyst Sean Laaman raised the firm’s price target on Immunocore (IMCR) to $36 from $34 and keeps an Equal Weight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore price target raised to $37 from $36 at Mizuho
- Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
- Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
- Immunocore Reports Strong Growth in Q3 2025
- Immunocore reports Q3 EPS 0c, consensus (24c)